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Abstract
Human blood plasma provides a highly accessible window to the proteome of any individual in 
health and disease. Since its inception in 2002, the Human Proteome Organization’s Human 
Plasma Proteome Project (HPPP) has been promoting advances in the study and understanding of 
the full protein complement of human plasma and on determining the abundance and 
modifications of its components. In 2017, we review the history of the HPPP and the advances of 
human plasma proteomics in general, including several recent achievements. We then present the 
latest 2017-04 build of Human Plasma PeptideAtlas, which yields ~43 million peptide-spectrum 
matches and 122,730 distinct peptide sequences from 178 individual experiments at a 1% protein-
level FDR globally across all experiments. Applying the latest Human Proteome Project Data 
Interpretation Guidelines, we catalog 3509 proteins that have at least two non-nested uniquely-
mapping peptides of 9 amino acids or more and >1300 additional proteins with ambiguous 
evidence. We apply the same two-peptide guideline to historical PeptideAtlas builds going back to 
2006 and examine the progress made in the past ten years in plasma proteome coverage. We also 
compare the distribution of proteins in historical PeptideAtlas builds in various RNA-abundance 
and cellular localization categories. We then discuss advances in plasma proteomics based on 
targeted mass spectrometry as well as affinity assays, which during early 2017 target ~2000 
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proteins. Finally we describe considerations about sample handling and study design, concluding 
with an outlook for future advances in deciphering the human plasma proteome.
Graphical Abstract
Keywords
Human Proteome Project; mass spectrometry; plasma; proteomics
Introduction
Human blood is the most informative easily obtainable sample for assessing the wellness of 
an individual. Cells can be isolated to provide genomic, transcriptomic, proteomic, 
metabolomic, and epigenomic information, and the plasma can yield a wealth of systemic 
information based on the abundance of proteins, cell-free DNA and RNA, metabolites, 
lipids, and other small molecules. Blood is in contact with all internal organs and, therefore, 
contains signatures of normal function as well as the consequences of cellular damage and 
disease manifestation throughout the body. However, the abundances of proteins and other 
molecules vary across an enormous dynamic range (~1013 range), making the task of 
detecting and quantifying low abundance signatures a difficult challenge (1). The plasma 
proteome, therefore, is immensely important clinically and presents enormous analytical 
challenges.
As one of the very first initiatives of the Human Proteome Organization (2) (HUPO), the 
Human Plasma Proteome Project (HPPP) began in 2002 with the aim of establishing a 
comprehensive profile of the proteins present in human plasma in health and disease. The 
initial phase of the HPPP was a collaborative effort among 35 laboratories to catalog the 
human plasma proteome via mass spectrometry (MS) based on a set of defined reference 
samples of plasma and serum (3). The HPPP continues its efforts to the present day with MS 
as well as exploring orthogonal technologies.
The global Human Proteome Project (HPP) was announced in 2010 at the 10th HUPO World 
Congress in Sydney, Australia, with the aim of advancing our understanding of all proteins 
in the human proteome and making advanced protein measurement assays more accessible 
to the broader research community (4). The HPP comprises a chromosome-centric project 
(C-HPP; launched at HUPO 2011 in Geneva, Switzerland) (5) that aims to identify and 
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characterize all proteins, annotated in an internationally distributed fashion; a biology/
disease-focused project (B/D-HPP; launched at HUPO 2012 in Boston, USA) (6) that aims 
to understand better the complement of human proteins that are pertinent to a wide variety of 
human organ systems and biofluids in health and disease; and three resource pillars, 
including antibody profiling, mass spectrometry, and knowledge base/bioinformatics. The 
HPPP is one of the major initiatives of the B/D-HPP, focused on understanding the full 
complement of proteins that can be detected and measured in human plasma samples both in 
normal and diseased states.
In this article, we first provide a brief review of the advances of the HPPP and MS-based 
human plasma proteomics in general over the past 15 years. We present the latest and most 
comprehensive compendium of proteins that have been confidently detected in human 
plasma samples from the aggregated spectra generated in a large number of publicly 
available studies. We then discuss advances in MS, present other technologies beyond MS, 
and conclude with recommendations and an outlook for progress for the next five years.
Historical Perspective of Plasma Analysis with MS
The earliest large compendium of plasma proteins was presented in 2002 in the seminal 
article by Anderson & Anderson (1). The list of 289 proteins was collected from literature of 
the day. In a classic figure, a subset of proteins with abundances was depicted over 10 orders 
of magnitude in abundance in normal plasma and grouped broadly into the categories of 
classical plasma proteins, tissue leakage products, and cytokines and other very low 
abundance proteins. Most of the proteins were listed in a table with typical reported 
concentrations from ELISA (or similar technology) measurements.
In 2003 the HPPP obtained and distributed a series of serum and EDTA-, citrate-, and 
heparin-anticoagulated plasma samples from Caucasian, African-American, and Asian-
American individuals to 35 different laboratories to run across a range of MS instruments 
and analysis of choice and report the resulting lists of peptides and proteins. There was 
tremendous variability in the reported results, with some groups providing a rather shallow 
analysis of one or two of the distributed samples, while other groups provided a far deeper 
analysis with substantial fractionation of many more samples. This heterogeneity made it 
particularly difficult to compare results among different groups. In the final HPPP report (3), 
the number of non-redundant proteins with one or more peptides reported by any group was 
over 9000. A more conservative list of proteins with at least two reported peptides amounted 
to 3020 proteins and those with three peptides to 1500 proteins. The danger of very high 
numbers of false positives from combining many such data lists was explicitly suspected. A 
subsequent, far more conservative analysis of the results by the same HPPP investigators 
concluded that there existed high confidence evidence for 889 proteins (7). This analysis 
uniquely used a Bonferroni-type adjustment for multiple comparisons. An independent 
analysis of the raw data from most (but not all) of the labs as well as some additional data 
sets yielded a similar estimate of 960 proteins (8).
Around the same time, several other labs made attempts at defining the MS-observable 
human plasma proteome. In retrospect, some of these attempts also suffered from 
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substantially inflated numbers due to improperly controlled false positives. In 2008, a 
meticulous manually-validated effort using the latest instrumentation yielded only 697 
proteins, albeit with 144 immunoglobulin entries removed (9). Although combining data sets 
from different investigators and platforms provides access to a higher number of legitimate 
detections, it also makes controlling the false discovery rate (FDR) far more challenging.
It was widely recognized that the most abundant proteins greatly complicated detection of 
much lower abundance proteins and their peptides. Antibody-based depletion of 1 (albumin), 
6, 14, or 22 most abundant proteins (accounting for 50 to 99% of the protein mass) became 
common (10–12), with deeper in-house depletion methods also recently developed (13, 14).
Subsequently the PeptideAtlas resource collected many additional data sets from many 
different labs and provided substantial effort into controlling the FDR of the search results to 
provide a database of human plasma proteins with an approximate 1% FDR at the protein 
level across all experiments as an ensemble. In 2011 Farrah et al. reported 1929 proteins 
with a 1% protein-level FDR, along with estimated concentrations of the identified proteins 
based on PSM counting statistics across all datasets in the PeptideAtlas build (15). In 2013, 
3553 non-redundant proteins were reported (16). In 2014, Farrah et al. extensively compared 
the proteomes of plasma, kidney, and urine, detecting proteins filtered from the plasma 
through the kidney to the urine, proteins appearing de novo in the urine, and proteins arising 
in the kidney (17).
More recent work has pushed the number of confidently-identified plasma proteome even 
higher. Keshishian et al. (18) reported on human plasma derived from four patients 
undergoing a planned myocardial infarction procedure for hypertrophic cardiomyopathy. 
Plasma was sampled at multiple time points, depleted of the ~64 most abundant proteins, 
cleaved with two proteases, labeled with iTRAQ reagents, fractionated by pH 10 RP-HPLC 
into 30 concatenated pools, and analyzed with modern high resolution Q Exactive Plus 
Orbitrap instrumentation. Whereas 3400 proteins were quantified in every sample, a total of 
5300 distinct protein entries were claimed in at least one of the samples, with an estimated 
protein-level FDR <0.02% (1 decoy/5304). Alternative strategies attempt to minimize the 
total analysis time in an effort to make plasma proteomic analyses more clinically 
accessible. Recent efforts achieve high quantitative repeatability of ~1000 proteins using a 
single MS run per sample (19), in one case analyzing 1294 separate plasma proteomes (20).
The Human Plasma PeptideAtlas 2017
The PeptideAtlas project (21–23) has been collecting shotgun proteomics datasets from labs 
all around the world since 2004, processing the raw data through a uniform analysis pipeline 
based on the Trans-Proteomic Pipeline (24–26), and publicly releasing ensemble builds of 
all the processing results, for human and many other species for which substantial data were 
collected (27–34). For some species such as human, where samples from different tissue and 
biofluid type are available, PeptideAtlas has created special builds focusing only on a single 
sample type. The earliest such special build was for human plasma in 2005 (8); and this has 
been updated many times since. The Human Plasma PeptideAtlas has provided a publicly 
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available, high stringency snapshot of the full complement of proteins detected in plasma in 
publicly available shotgun MS experiments over time since 2005.
Since our last publication in 2014 (17), three additional builds have been released on-line in 
2014 (unpublished), 2015 (unpublished), and 2017-04 (presented in this article). The latest 
build follows the same data analysis and FDR calculation procedures described in the 2014 
publication, with the exception that the search database now used is the THISP database, 
which is based on neXtProt (Deutsch et al, JPR2016). Thresholds for all individual datasets 
are set so that when all combined, the combined protein-level FDR is 1%, with a 
corresponding combined PSM-level FDR of 0.0005 and a combined peptide-level FDR of 
0.004. Further statistical details are displayed on the build summary page at the PeptideAtlas 
interface. Figure 1 depicts the total number of distinct peptides as a function of the total 
number of PSMs passing threshold added to the Human Plasma PeptideAtlas over time from 
the earliest datasets to the most recent. The dramatic increase in the number of distinct 
peptides heralds the advent of the collection and analysis of high resolution MS2 spectra 
with Orbitrap-based instruments.
Supplementary Table 1 lists all 178 experiments included in the latest build. Each 
experiment represents a distinct analyzed sample. Some samples are single MS runs, while 
in most experiments samples were fractionated to reduce complexity before each fraction 
was analyzed in a separate LC-MS run. In many cases, data sets that are submitted as a 
single ProteomeXchange dataset are separated into individual experiments when they 
represent different samples. For each experiment, attributes such as the total number of MS2 
spectra, number of PSMs passing threshold, number of distinct peptides, etc. are listed. The 
2017-04 build now contains 122,730 distinct peptides (including many semi-tryptic ones) 
derived from over 43 million PSMs that pass threshold, selected from a total of 172 million 
spectra searched. The number of proteins listed in Supplementary Table 1 is somewhat 
higher than the 3509 number listed in other parts of this article because the numbers in the 
supplementary table includes contaminants, alternative splice isoforms, variable region 
immunoglobulin sequences, and other TrEMBL entries with apparently unique peptides 
mapping to them, while the 3509 number is limited to just the ~20,000 neXtProt protein 
entries.
In order to gain a historical perspective on the total number of proteins gained for each of 
our consecutive builds in a consistent manner, we have remapped all the peptides from these 
builds to the 2017-01 version of neXtProt using the AtlasProphet algorithm (23). We have 
applied guideline # 15 of the HPP MS Dataset Interpretation Guidelines (35) such that for a 
protein to be listed as canonical in PeptideAtlas, it must have two distinct non-nested, 
uniquely mapping peptides of length ≥9 residues. In Figure 2, we show the progression of 
the number of these canonical proteins over historical builds, culminating in 3509 proteins in 
the 2017-04 build. Note that these numbers are smaller from those quoted in previous 
publications because new, stricter requirements have been imposed on the older data to 
reduce misidentifications. In addition, there are 1337 proteins in the ambiguous category; 
these include proteins with only one peptide, peptides of insufficient length, and cases where 
the detected peptides cannot distinguish between members of a group, although clearly at 
least one of the members of the group has been detected. A further 1700 entries are in a 
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redundant category, meaning that although there are peptides that map to these entries, those 
peptides are better assigned to a canonical or ambiguous protein using rules of parsimony.
In Figure 3 we compare the overlap between the lists of proteins in builds 2009 – 2017. A 
core set of 984 proteins are found in all of these builds, with 1153 added in 2013, 785 
progressively added in 2015, and 573 progressively added in 2017. Only 14 proteins that 
were present in the 2009 and 2010 builds were lost in later builds. These correspond to 
identifications that were marginally above threshold in earlier builds, but below in later 
builds; thresholds must become more stringent with every build as more data are added in 
order to maintain a similar overall FDR. These 14 proteins are most likely false positives not 
borne out with far more data, implying a minimum FDR of 1.4% in the 2009 and 2010 
builds. The 2013, 2014, 2015 builds have only a handful of protein entries not corroborated 
or carried through in later builds. There were 714 proteins with 2 peptides in the 2006 and 
2007 builds that were not corroborated in any of the subsequent builds, suggesting very high 
FDRs of perhaps 20% in these earlier builds, although some of the discrepancy may be due 
to N-glycosylation enriched proteins as well as the requirement that the peptides be ≥ 9 aa.
We have also estimated average protein concentrations for canonical proteins in the latest 
2017 build as well as older builds in order to compare the distributions of concentrations of 
added proteins as the Atlas expands. Concentrations were estimated based on the total 
number of PSMs for canonical proteins, corrected for the number of expected tryptic 
peptides of suitable attributes, and calibrated against a list of known protein concentrations, 
a method previously described in detail for the 2010 Human Plasma PeptideAtlas build by 
Farrah et al. (36). Figure 4 depicts the distribution of estimated protein concentrations from 
builds in 2010, 2013, 2015, and 2017. The mean of the distributions clearly moves to lower 
concentration from 2010 to 2013 to 2015. However, the shape of the distribution remains 
highly similar from 2015 to 2017, with very few proteins extending below 0.01 ng/ml 
estimated concentration. These concentrations are estimated based on a combination of all 
samples, which vary widely in instrumentation, quantification methods, degrees of 
fractionation, and sample preparation techniques. It would be useful to be able to estimate 
and provide plasma protein concentrations in specific physiological contexts or disease 
states, but data to provide that are not currently available; a highly uniform survey for 
plasma concentrations under carefully controlled specific physiological contexts or disease 
states would provide very valuable data.
All data associated with this build are made publicly available in the PeptideAtlas Data 
Repository and via links at http://www.peptideatlas.org/hupo/hppp/. This includes raw data 
and search results from each of the included experiments, listed with links at http://
www.peptideatlas.org/hupo/hppp/repository/. The data are available packaged in BDBags 
that are uniquely identified with Minids (37). BDBags are compressed archives that contain 
embedded manifests and checksums that enable automated validation of completeness 
against the checksums. Minids provide a convenient and short minimal identifiers that can 
uniquely identify datasets and enable users to download and verify them using the associated 
toolset (http://minid.bd2k.org/).
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Comparisons with RNA abundances
In order to compare the expansion of the proteome with overall RNA abundance, we group 
RNA abundance in tissues as compiled by the Human Protein Atlas (HPA; version 15) into 
four broad categories (high: FPKM > 50, medium: FPKM 10–50, low: FPKM 10-0.5; not 
detected: FPKM 0.5-0) (38, 39)). We note that correlation between RNA abundances and 
protein abundances is a subject of extensive discussions and generally low (e.g. (40)), but the 
completeness of RNA abundances is far higher and enables nearly complete comparisons 
with several protein sets. In Table 1 we show the relative distributions of proteins within 
these high, medium, low and not detected categories. While 42% of the population of all 
protein-coding genes from Ensembl (release 88.38) falls into the high RNA-abundance 
category in highest-expressed tissues, a somewhat higher percentage (50%) of proteins 
detected in all human samples are in this high abundance category, and in the Plasma 
PeptideAtlas an even higher percentage (77%) are in this high RNA abundance category. 
The total number of plasma proteins differs slightly from the figure of 3509 in the abstract 
and other totals in this article because there is a small number of proteins that could not be 
mapped to the RNA expression tables.
The union of a broad range of immunoassays publicly available for plasma analysis during 
spring of 2017 was collected from five providers. The corresponding protein-coding genes 
for these targets were annotated with regards to their predicted location and RNA abundance 
using HPA: Somalogic (N = 1278), Olink (N = 978), R&D Systems (N = 540), Myriad RBM 
(N = 302) and Abcam (N = 238). For immunoassays, a greater number of targets are 
represented in the low RNA-abundance category than for the Plasma PeptideAtlas. The 
union of the 1918 proteins targeted by immunoassays and the 3429 Plasma PeptideAtlas 
proteins overlap by 1087 proteins.
In Table 2, we show the distribution of proteins detected in the Human Plasma PeptideAtlas 
over time as a function of RNA abundance categories from the Human Protein Atlas. In 
2009, only ~10% of the proteins in the Plasma PeptideAtlas were found in the medium and 
low RNA-abundance categories, while as of 2017, nearly a quarter of all high-confidence 
detections are proteins with corresponding medium and low RNA-abundance. The 
distributions of plasma protein concentrations in relation to these RNA expression categories 
can be found in Supplementary Figure 1.
In Table 3, we used the protein abundance from the 2017 Human Plasma PeptideAtlas to 
show the concentration distribution and increase in coverage from previous builds. A 33-fold 
increase in coverage was seen for low abundant proteins (< 0.1 ng/ml).
In Table 4, we show the numbers and percentages of proteins in the Plasma PeptideAtlas 
builds since 2009 in relation to their localizations predicted from protein sequences (39, 41). 
Between 2015 and 2017, the coverage for secreted proteins hardly changed, accompanied by 
a marked increase in the percentage of membrane and intracellular proteins.
For the 2017 build, the distributions of concentrations in relation to the predicated protein 
localization (categorized in intracellular, secreted and membrane only) are illustrated in 
Supplementary Figure 2.
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Targeted MS assays for the plasma proteome
While most of the efforts to expand the known plasma proteome have used shotgun 
proteomics techniques, the selected reaction monitoring (SRM) technique has been widely 
used to achieve more consistent, quantitative, and sensitive measurements of specific 
proteins of interest in plasma. SRM workflows are more difficult to deploy due to the 
requirement for predetermining effective signatures for each targeted protein, the need for 
spiking in heavy-labeled reference peptides for accurate quantitation, and the limited number 
(~200 – 1000) of those signatures that can be monitored per MS run. However, this extra 
effort required to carry out measurements is offset by improved sensitivity and specificity, 
high degree of quantitative accuracy and reproducibility, and the determination of upper 
limits of abundance for each targeted peptide. The earliest work by Anderson & Hunter (42) 
developed targeted assays (also known as multiple reaction monitoring (MRM) targeting 53 
high and medium abundance proteins over 4.5 logs in abundance with a coefficient of 
variation (CV) of < 10% for most of them. This was followed by many other studies that 
have defined and demonstrated the effectiveness of signatures for certain proteins of interest 
(43–46). Of particular interest was the deployment of SRM assays over several MS runs for 
over 1000 cancer associated proteins and the detection of 182 of these cancer associated 
proteins in plasma covering 5 orders of magnitude (47).
To provide assistance in deploying targeted SRM assays, the SRMAtlas resource (48) was 
developed using highly characterized synthetic peptides representing the most proteotypic 
candidates of each protein, their variants, including spliced and non-synonymous variants, 
and some post-translational modifications. The human SRMAtlas has now determined 
recommended signatures for multiple peptides per protein for over 99% of all human 
proteins, enabling researchers to target any protein of interest without needing to undergo a 
lengthy signature selection process, fragment ion selection and SRM assay construction.
To further advance targeted quantitative proteomics, multiplexed fragment ion monitoring 
based assays have been developed into a technique, broadly termed data-independent 
acquisition (DIA), including SWATH-MS (49). SWATH-MS promises to provide similar 
sensitivity and specificity as SRM, without the problems associated with selecting targets in 
advance, by utilizing a well characterized spectral library developed a priori or on the fly 
(50, 51). In essence, high-resolution fragment ion data are collected for all peptides across 
chromatographic peaks above the detection threshold in a sample, but at the cost of 
substantially more complex informatics analysis after acquisition, which is needed to 
disentangle the high level of multiplexing in the data. DIA techniques perform well in 
comparison with SRM (52). Large scale-studies of over 1000 plasma proteins in many 
plasma samples are now feasible (53, 54), and also enable the study of unexpected post-
translational modifications within the comprehensive multiplexed datasets (55, 56).
Affinity assays for the plasma proteome
As described above, the main driving force for defining new components of the plasma 
proteome has been mass spectrometric. An alternative for determining the constituent 
proteins in plasma is the use of affinity reagents to capture, enrich, and detect their target 
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proteins. The use of such assays has provided general as well as clinically applied insights 
into the protein composition of body fluids, starting from albumin down to low abundance 
molecules, such as cytokines.
Affinity-based approaches require knowledge about which proteins are to be measured, and 
hence are by definition targeted assays. A primary bottleneck for expansion to a wider range 
of proteins has been linked to the availability of affinity reagents (57). According to 
Antibodypedia (www.antibodypedia.org; access date 2017-05-11; (58)) there are more than 
2.8 million antibody reagents commercially available. Even though these cover 94% of the 
protein encoding genes, enormous effort is still required to validate and annotate their utility 
for the intended assay type and technology platform, as well as the sample type, preparation 
and formulation. For highly multiplexed assays, compatibility between different assay 
components also needs further attention. Recent discussions have indeed raised concerns 
about the reliability of affinity-based assays due to lack of reproducibility and specificity 
(59, 60). The community has therefore brought forward suggestions for how to apply 
communal standards on how to validate these reagents (61). The performance of reagents is 
indeed dependent on the application and sample type and needs to be assessed for every 
binder and every assay. A systematic approach using MS to qualify antibodies for their use 
in plasma proteomics assays has just recently been described (62). While the generation of 
natural or synthetic affinity reagents is discussed in detail elsewhere (63), and an increasing 
diversity of reagent types is making them attractive across the different fields of life science, 
they must be assessed separately for their use in plasma assays and the applied technologies.
Assay platforms
Today there are a variety of multiplexed assay technologies available to detect proteins in 
plasma (64). Whereas affinity reagents are also used in combination with MS (65, 66), the 
primary applications for plasma are driven towards high throughput assays in terms of 
sample and proteins. Here, multiplexing is achieved by different concepts such as coding the 
features either via their location (e.g. on a planar support or in channels) or with color or 
DNA barcode. Detection is then most often achieved via fluorescently labelled reporters or 
barcodes of oligonucleotides for amplification, hybridization or sequencing. A general 
feature of multiplexed affinity assays is that small quantities of samples (< 50 μl) suffice for 
a single highly multiplexed analysis or sets of medium-sized multiplexed analyses. Pre-
fractionation is generally not required. In addition, larger sets of samples (N > 100) can be 
analyzed within a single lab day, since most assays are performed in microtiter plates for 
which automation solutions exist. Technological advances have further led to the availability 
of assays with very high sensitivity (fg/ml) (67). Nevertheless, the number of protein assays 
and degree of multiplexing remains limited in most applications, in particular when 
compared to MS. Challenges for immunoassays relate to interference, incompatibility of 
assay components causing cross-reactivity, different sample dilutions needed for reaching 
the optimal analytical window, assay specificity, and analytical selectivity (68).
In the long run, technologies that are capable of measuring proteins in multiplex and in a 
large number of samples will be beneficial for rapid analysis of plasma (69). One attractive 
solution is described for coupling multiplexed protein detection with read-out by DNA and 
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to profile more than 90 proteins in a single assay (70, 71); they have been used and applied 
in extensive sample sets (72, 73). While these proximity extension assays use two binders 
per target protein, other large scale techniques employ single affinity reagents for high 
multiplexing capabilities. Those exist on planar arrays (74) as well as on color-coded beads 
(75), but both come at the expense of sensitivity and specificity, hence require complex 
validation schemes to assure the identity of the captured protein (76). Another single binder 
concept that has seen broad usage is based on modified aptamers that have been engineered 
to both enrich proteins from plasma and serve as the detection agent (77). The signatures of 
the obtained plasma profiles were associated with the protein quantitative trait loci (pQTLs) 
for validation (78). Recently, the system has been expanded in the number of targets per 
assay to 3000 proteins (79), and assays with 5000 proteins are under development although 
have not been released as of September 2017 (personal communication). The utilized 
selection technology and introduction of additional modifications may be one approach to 
enable the generation of even larger libraries of affinity binders, possibly reaching a possible 
proteome-wide coverage (80).
To provide insights into the current portfolio of immunoassays with data from MS, we 
collected protein assays offered by five commercial immunoassays providers, as introduced 
above (see Comparisons with RNA abundances). Cumulatively, these five resources 
constituted 1918 unique targets as of spring 2017, and provide an alternative starting point 
for a description of the protein assays with plasma. Out of these 1918 proteins, a set of 831 
proteins were only detectable by immunoassays when compared to the 2017 build of the 
Human Plasma PeptideAtlas, leaving 1087 proteins detected in both. The 2017 Human 
Plasma PeptideAtlas contained a further 2422 proteins that remained addressed only by MS-
based methods. We investigated the functional differences between the proteins covered by 
the two technologies by assessing their Gene Ontology (GO) term distribution using 
ToppCluster (81). This revealed that terms for cytokine related proteins were enriched for 
immunoassays (GO:0005126, GO:0005125, GO:0008009, GO:0042379). For MS, terms 
related to structural elements (GO:0005198, GO:0008092, GO:0003779, GO:0051015) were 
enriched (see also Supplementary Table 2). This indicates that (i) many low abundant 
proteins are still difficult to detect in plasma when using MS and that (ii) cellular proteins 
are found in plasma but are underrepresented in the portfolio of immunoassays. Lastly, our 
investigation revealed 1087 proteins found to be detectable with both technologies. GO 
analysis for these proteins revealed terms such as protein complex binding (GO:0032403; N 
=172), extracellular space (GO:0005615; N =466), cell mobility (GO:0048870; N =304), 
localization (GO:0051674; N =304) and cell migration (GO:0016477; N =295). These 
~1000 proteins can provide a starting point for comparing the two technologies with the 
purpose of validating each other in increasing numbers of samples, studies and diseases. 
Eventually, databases such as PeptideAtlas should also be created for the widely used 
immunoassays to collect data and the concentrations of proteins found in plasma. These 
initiatives could also follow examples of the NCI assay portal (82) that currently hosts 1,517 
quantitative mass spectrometry-based proteomic assays targeted for 820 proteins. In this 
portal, 374 assays listed for plasma or serum derived samples target 192 unique proteins.
Affinity assays will assist in our understanding of the plasma proteome once validated and 
sensitive assays exist for even more protein targets and for those currently not detectable by 
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MS. The immunoassays are attractive for studies with larger sample numbers, especially if 
the amount of material is limited, but still less for de novo discovery purposes. 
Quantification remains a challenge for today’s immunoassay, since different standards are 
often used by different assay providers, and their detectability may differ from that of the 
protein found in-vivo. The emerging systems that offer either highly multiplexed or highly 
sensitive assays will accelerate our knowledge about the plasma proteome and move beyond 
the well-studied markers of inflammation. Specificity also remains a major challenge for 
affinity assays, as reflected in the goals of the International Working Group on Antibody 
Validation (61).
Considerations about samples in plasma proteomics
Studies aiming to determine the plasma proteome have largely been limited either by the 
number of targets or in terms of sample numbers. It is therefore likely that, if only a few 
phenotypes are used, the initial indications cannot be confirmed in an independent set of 
samples. Hence, the sample number of plasma proteomic studies must increase. 
Furthermore, plasma is a specimen that is attractive because it is accessible from a large 
number of subjects and frequently hosted by biobanks, although many are populated mainly 
with blood sera (83). Since the recommendations of the Human Proteome Project in 2006 
(3), most plasma samples have used EDTA as anticoagulant; however, some specimens are 
still anticoagulated with heparin or citrate. Further, multitudes of dried blood spot cards 
known as Guthrie cards are available since the early 1960’s for all newborns almost 
worldwide providing a large resource for blood-based proteomics (84–86). This provides 
opportunities for new discoveries and is assisted by expanded metadata about each donor 
(health status and history) as well as the pre-analytical conditions related to the sample. 
However, both must be acknowledged and considered more carefully. The community is 
indeed becoming more aware that these sample related parameters may contribute to the 
detectability of a protein and thereby influence the outcome and reproducibility of a study 
(87–89). Hence, guidelines for the parameters related to the sample, such as blood draw 
(time point of collection, location), collection procedure (tube type, handling conditions), 
storage (aliquoting, container, temperature), use (thawing procedure, freeze-thawing cycles) 
as well as alternative formulation (dried plasma or blood spots), should therefore be 
considered and included in the experimental planning and downstream data analysis. A 
categorization of sample-related parameters can already be obtained (90) and a wider use of 
such codes will further enhance the validity of studies in plasma.
Conclusion
The advances in MS technologies continue to push our ability to detect and quantify a large 
number of proteins with high specificity and quantitative accuracy. Yet, affinity capture 
reagent technologies outperform MS in terms of sensitivity and speed. Ongoing efforts to 
better characterize affinity capture reagents in a given sample holds the potential to improve 
the specificity and reliability of the assays in which these are used. The combination of these 
two technologies is probably underutilized today, having the potential to combine the 
sensitivity of affinity capture and specificity of MS, albeit still with the lower speed of MS.
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We have presented the 2017-04 latest build of the Human Plasma PeptideAtlas, with 3509 
core neXtProt proteins meeting guideline # 15 of the HPP MS Data Interpretation 
Guidelines. In comparison with older plasma builds, the addition of datasets with high 
resolution MS2 spectra have dramatically increased the number of distinct peptides observed 
and the sequence coverage, although the increase in the number of proteins was less 
pronounced. More datasets will be added as they are deposited into the public 
ProteomeXchange repositories. Datasets that use new instrumentation, additional proteases 
beyond trypsin, and additional enrichment strategies are most likely to continue increasing 
the total number of proteins successfully detected in human plasma samples via MS. 
Challenges remain—when is the project considered closed? Human variability is enormous 
and so individual differences in the plasma proteome will be apparent and cloud the analyses 
and interpretation. For example, tissue leakage markers from growing juveniles need to be 
distinguished from similar or identical markers present in adults undergoing tissue healing 
and repair after pathology or injury. Moreover, nutritional status, diurnal variation and 
hormonal status will all need to be considered and hallmark proteins subclassified 
accordingly. Nonetheless, annotating the Human Plasma Proteome Project heralds an 
important achievement necessary to define and form baselines for disease biomarker 
discovery and monitoring before and during treatment.
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Figure 1. 
Number of distinct peptide sequences in the Human Plasma PeptideAtlas 2017-04 as a 
function of the total number of PSMs included (43 million). Each box represents one 
experiment. The width of the box corresponds to the total number of PSMs passing 
threshold. The total height of the boxes (blue+red) represents the cumulative number of 
distinct peptide sequences in the build (culminates at 122,730). The height of the blue boxes 
corresponds to the total number of distinct peptide sequences in each experiment.
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Figure 2. 
Progression of the number of canonical proteins (using HPP Guidelines metrics) of 
historical Plasma PeptideAtlas builds. Builds since 2009 (in blue) do not contain N-
glycosylation enriched datasets and were thresholded at a ~1% protein-level FDR prior to 
application of guideline 15 requirements. Builds prior to 2009 (in orange) contain N-
glycosylation enriched datasets and were thresholded at a distinct peptide probability ≥ 0.9 
prior to application of guideline 15 requirements.
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Figure 3. 
A non-proportional 5-way Venn diagram depicting the overlap of canonical proteins in 
Human Plasma PeptideAtlas builds 2009 – 2017; 2013 and 2014 builds are combined 
because they are very similar. A core set of 984 proteins are found in all of these builds, with 
1153 proteins added in 2013, 785 progressively added in 2015, and 573 progressively added 
in 2017. The number 714 in the lower corner represents the numbers of proteins unique to 
the 2006 and 2007 builds, which are now known to have quite high FDRs.
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Figure 4. 
Relative distributions of estimated human plasma protein concentrations from four Human 
Plasma PeptideAtlas builds from 2010 to 2017. The mean of the distributions has moved 
markedly to include more proteins at concentrations below 1 ng/ml from 2010 to 2017.
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